Escolar Documentos
Profissional Documentos
Cultura Documentos
2010
2011
2012
2013
A multidisciplinary approach... A multimodality blood conservation program... Recomendaes Classe I e Classe IIa
EPO em pacientes que recusam transfuso EPO em paciente com alto risco de anemia
EPO em pacientes que recusam transfuso EPO em paciente com alto risco de anemia
Quem tem alto risco de anemia ps op (sangramento aumentado e transfuso)? Idade avanada
> 65a?
Methods. A multicenter double-blind, placebo-controlled, parallel-group study involved 182 patients having coronary artery bypass grafting and randomized to receive Epoetin alfa (300 or 150 IU/kg) or placebo subcutaneously for 5 days before, on the day of, and for 2 days after operation.
Cirurgia
Methods. A multicenter double-blind, placebo-controlled, parallel-group study involved 182 patients having coronary artery bypass grafting and randomized to receive Epoetin alfa (300 or 150 IU/kg) or placebo subcutaneously for 5 days before, on the day of, and for 2 days after operation.
Cirurgia
Methods. A multicenter double-blind, placebo-controlled, parallel-group study involved 182 patients having coronary artery bypass grafting and randomized to receive Epoetin alfa (300 or 150 IU/kg) or placebo subcutaneously for 5 days before, on the day of, and for 2 days after operation.
+ Ferro VO 3x
Cirurgia
In conclusion, a lower incidence of exposure to allogeneic blood transfusions was observed in both Epoetin alfatreated groups than in the placebo-treated group, but the differences between treatment groups were not significant. The treatment regimen and the route of administration were well tolerated in this patient population with no increase in adverse experiences compared with placebo treatment.
14.000
14.000
8.000
8.000
8.000
Cirurgia
10.000
10.000
10.000
10.000
10.000
10.000
10.000
10.000
+ Ferro VO 3x
Cirurgia
14.000 14.000 8.000 8.000
8.000
Cirurgia
Um cenrio